Much of the article, however, is actually about signs of impending conflict between the Justice Department and the FTC over the latter's effort to combat what appears (to the legal amateur) to be cartel-like behavior--inter-firm agreements in which name-brand drug manufacturers pay generic manufacturers to delay the introduction of rival products.
Stephen Labaton, "New View of Antitrust Law: See No Evil, Hear No Evil," New York Times, 5 May 2006, C5.
No comments:
Post a Comment